
Session addresses the challenges of implementing autologous/allogeneic cell gene therapies into scalable networks.
Nicholas Saraceno is Editor of Pharmaceutical Commerce. He can be reached at [email protected].

Session addresses the challenges of implementing autologous/allogeneic cell gene therapies into scalable networks.

A panel uncovers the value in meeting carbon-neutral goals by 2030.

Panel discussion uncovers how to alter one’s digital know-how for use in temperature-controlled supply chain.

Masterclass session addresses looking beyond a dashboard by added capabilities with added value.

A difference-in-differences analysis explores the correlation between direct-acting antiviral prescriptions for hepatitis C virus and the softening of state-level limitations.

Allen Jacques explains the history behind medications’ lack of supply, while offering ways to help alleviate their impact.

A cohort study digs into whether there is an improvement in overall survival or quality of life within five years of the FDA granting accelerated approval to oncology drugs.

Wattala warehouse is expected to offer both export consolidation and 3PL services for trade routes that link Africa, Asia, and Europe.

The collaboration strengthens the capabilities of Tower’s advanced passive temperature-controlled containers.

The acquisition initiates a long-term agreement with Beacon Therapeutics, highlighted by clinical and commercial AAV production.

The program recognizes organizations that prioritize the highest standards of care when it comes to the handling and transportation of goods in the healthcare space.

The new products offer more temperature control and sustainability benefits.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value & Access Advisor, Schoonveld Advisory, offers his thoughts on lower drug prices in the US and provides a sneak peak into future PC features.

The program intends to address pharmacy deserts, which are predominantly found in underserved communities.

The first commercial shipments are scheduled for mid-April.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value and Access Advisor, Schoonveld Advisory and author of The Price of Global Health, explains why pharmaceutical products tend to cost more in the US than the rest of the world.

Year-on-year growth in demand is strong, according to the IATA.

We'll be back in Lyon, France, this month to capture the latest insights and advances in pharma logistics—as leaders seek to build the supply chains of the future.

Pharma Commerce makes a return trip to Philly for insights on the latest approaches in patient assistance and adherence.

Cohort study examines the potential for spending to significantly decrease for individuals who use these generic versions of biologics.

Analysis determines the suggested value of medications for diabetes if they were closer to production costs.

Syneos Health's Kim Plesnarski uncovers the key issues that customers are currently trying to address, including the retail shift from small-molecule products to biologics.

Cross-sectional study explores the impact of this monumental Supreme Court ruling.

Qualitative study breaks down challenges and priorities of the Medicare Shared Savings Program, as noted by affordable care organizations.

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.

Five of the company’s vaccines are currently in Phase III.

A study investigates how a New Mexico law can impact patients’ out-of-pocket costs surrounding mental health and substance use disorder medications.

The new option will help patients receive life-saving medications at an even quicker rate.

A study of patients with the long-term conditions who are required to switch to high-deductible health plans could potentially be more likely to experience diabetes complications than those who stay in standard insurance plans.

The organizations conducted an in-depth study of the program over the course of two years, publishing a white paper on the findings.